
We are currently investigating new therapeutic targets for small molecule and gene therapy-based approaches for Parkionson disease and related disorders. Our research aims to translate the identification of novel therapeutic targets for Parkinson disease into the validation of those targets in the most relevant experimental models and into subsequent proof-of-principle for potential efficacy.